Posted by Michael Wonder on 08 Sep 2022
ViewRay announces China NMPA approval of its MRIdian MRI guided radiation therapy for cancer patients
7 September 2022 - This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option—MRIdian SMART.
ViewRay today announced that the company's MRIdian MRI guided radiation therapy system has received approval from the Chinese regulatory authority National Medical Products Administration, allowing for its sale and utilisation throughout China.
